# GLMD earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/GLMD) · [Earnings tab](https://www.lopjlb.com/stock/GLMD?tab=earnings)

Updated: 2026-08-17T06:19:30

Quarters analyzed: 8

## Cross-quarter narrative

Across the 2020‑2021 earnings calls Galmed’s discourse shifted from early pandemic‑driven uncertainty and delayed ARM ARMOR recruitment to a more confident tone as FDA alignment on the Aramchol‑meglumine formulation was secured and cost‑saving measures cut COGS by roughly half. Initial calls highlighted COVID‑related enrollment halts, lowered guidance and cash burn concerns, while later quarters emphasized resumed enrollment, positive open‑label histology data, and progression of the Amilo‑5MER program. The company moved from speculative guidance to concrete milestones such as the FDA agreement for Phase 3 dosing, the ARCON interim readout, and the completion of Amilo‑5MER Phase 1. Despite these advances, recurring themes of regulatory approval risk, competitive pressure in NASH, and the need for continued enrollment momentum persisted, underscoring a balanced outlook between operational progress and lingering uncertainties.

## Latest CallCard · Q4

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2021 Q4:** —
- **2021 Q3:** Galmed presents positive ARCON open-label data showing 60% fibrosis reduction with higher-dose Aramchol, supporting potential accelerated Phase 3 interim analysis.
- **2021 Q2:** Galmed secures FDA agreement to use Aramchol meglumine in Phase 3 ARMOR study, enabling once-daily dosing and 50% COGS reduction; open-label data from 50 patients expected Q4 2021; Amilo-5MER Phase 1 complete; cash $51.2M.
- **2021 Q1:** Galmed outlined ARMOR study biopsy readout expected Q4 2021, IND approval in China, pending FDA feedback on meglumine, and COVID‑related site selection impacts.
- **2020 Q4:** Galmed outlined ARMOR Phase 3 re‑initiation in Q1 2022 targeting data readout by Q2 2024, noted a $70‑80 M budget range, highlighted Amilo‑5MER Phase 1b start H2 2021, and expressed high confidence in meeting timelines despite COVID‑19.
- **2020 Q3:** Galmed reports Q3 loss, advances Aramchol meglumine PK data expected Dec, ARMOR enrollment slowed by COVID second wave in US/Europe, new collaborations with Gannex (TRβ agonist) and MyBiotics (microbiome) to enhance efficacy.
- **2020 Q2:** Galmed maintains ARMOR Phase III guidance (Q4'21 recruitment, H2'23 top-line) despite COVID-19; advances Aramchol meglumine bioequivalence (Q3'20 prelim, Q2'21 regulatory) and Amilo-5MER Phase I in Q4'20 for IBD/COVID-19; cash $63.5M.
- **2020 Q1:** Galmed reports Q1 2020 results, announces Aramchol meglumine NCE with 30,000x solubility, plans FDA transition in ARMOR Phase 3, delays recruitment guidance to Q4 2021 due to COVID-19, cash $69M.

## Theme arcs

- **ARMOR enrollment** (improving): Initial COVID delays gave way to re‑initiation and on‑track open‑label cohorts
- **Regulatory alignment** (improving): FDA acceptance of meglumine formulation achieved after earlier uncertainty
- **Financial runway** (stable): Cash reduced but cost cuts and runway extensions maintained
- **Competitive landscape** (deteriorating): New Phase 2 programs from Novo and Gilead heightened market risk
- **Data generation** (improving): Positive ARCON histology results and upcoming biopsy readouts
- **Manufacturing/bioequivalence** (new): Bioequivalence study introduced as a critical path item

## Fear persistence

- **Regulatory risk** [recurring]: Ongoing concerns about FDA acceptance of meglumine and IND pathways
- **Enrollment/recruitment risk** [recurring]: COVID‑related site disruptions and geographic enrollment balance
- **Competitive risk** [recurring]: Emerging NASH programs from Novo, Gilead and others
- **Budget/financial risk** [recurring]: Uncertainty around ARMOR program cost and cash runway
- **COVID‑19 risk** [recurring]: Potential for further site closures affecting timelines
- **Manufacturing/bioequivalence risk** [recurring]: Success of meglumine bioequivalence study critical for Phase 3

## Guidance path

2020 Q1:lowered → 2020 Q2:maintained → 2020 Q3:vague → 2020 Q4:maintained → 2021 Q1:maintained → 2021 Q2:vague → 2021 Q3:vague → 2021 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/GLMD`